StockSelector.com
  Research, Select, & Monitor Sunday, August 18, 2019 11:21:06 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
ImmunoGen, Inc.$2.83$.082.91%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  ImmunoGen, Inc. vs Drug Manufacturers/Other

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.




Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $53.5 Mil $98,897.9 Mil
  Market Cap: $419.2 Mil $338,972.0 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: (53.7%) 171.4%
  Estimated Revenue: (13.9%) 280.7%
  Historic Earnings: N/A 37.1%
  Estimated Earnings: N/A 67.3%
  Stock Price (1 Year): (68.0%) (10.7%)
  Cash per Share: (12.9%) 35.9%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: N/A 21.6
  Price-to-Sales: 8.6 N/A
  Price-to-Book: 38.5 1.5
  Dividend Yield: N/A N/A
  Market Cap: $419.2 Mil $13,037.4 Mil
  Operations
  Net Margin: (355.5%) (510.8%)
  Gross Margin: 100.0% 80.4%
  Return on Equity: (15.4) (.5)
  Return on Assets: (.6) .0
  Balance Sheet
  Current Ratio: 3.9 7.3
  Quick Ratio: 3.9 7.0
  Cash Ratio: 3.7 6.1
  Debt-to-Equity: 25.9 2.4
  Interest Coverage: .3 .7
 Technicals
  Relative-Strength Index: 63.1 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $51.66 $126,232.8 Mil
  Allergan plc  (AGN) $158.25 $51,874.4 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $184.94 $48,051.5 Mil
  UBS AG  (UBS) $10.40 $39,421.0 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $110.85 $25,007.8 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.